Literature DB >> 8913349

Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells.

J W Lawrence1, D C Claire, V Weissig, T C Rowe.   

Abstract

We have previously shown that 4-quinolone drugs cause a selective loss of mitochondrial DNA (mtDNA) from mouse L1210 leukemia cells. The loss in mtDNA was associated with a delayed loss in mitochondrial function. Here, we report that the 4-quinolone drug ciprofloxacin is cytotoxic to a variety of cultured mammalian cell lines at concentrations that deplete cells of mtDNA. The IC50 values for ciprofloxacin varied from 40 to 80 micrograms/ml depending on the cell line tested. Cytotoxicity required continuous exposure of cells to drug for 2-4 days, which corresponded to approximately three or four cell doublings. Shorter times of drug exposure did not cause significant cytotoxicity. In addition, cells became drug resistant when they were grown under conditions that bypassed the need for mitochondrial respiration. Resistance was not due to a decrease in cellular drug accumulation, suggesting that ciprofloxacin cytotoxicity is caused by the loss of mtDNA-encoded functions. Analysis of mtDNA from ciprofloxacin-treated cells revealed the presence of site-specific, double-stranded DNA breaks. Furthermore, exonuclease protection studies indicated that the 5'-, but not the 3'-, ends of the drug-induced DNA breaks were tightly associated with protein. These results suggest that ciprofloxacin may be causing cytotoxicity by interfering with a mitochondrial topoisomerase II-like activity, resulting in a loss of mtDNA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913349

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  30 in total

Review 1.  Mitochondria: a target for cancer therapy.

Authors:  Jeffrey S Armstrong
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

2.  Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.

Authors:  N Duewelhenke; O Krut; P Eysel
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

Review 3.  Mitochondrial medicine: pharmacological targeting of mitochondria in disease.

Authors:  J S Armstrong
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

4.  Oral fluoroquinolones and risk of fibromyalgia.

Authors:  Saeed Ganjizadeh-Zavareh; Mohit Sodhi; Tori Spangehl; Bruce Carleton; Mahyar Etminan
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

5.  Effects of ciprofloxacin-containing antimicrobial scaffolds on dental pulp stem cell viability-In vitro studies.

Authors:  Krzysztof Kamocki; Jacques E Nör; Marco C Bottino
Journal:  Arch Oral Biol       Date:  2015-05-16       Impact factor: 2.633

6.  Calcium signals are affected by ciprofloxacin as a consequence of reduction of mitochondrial DNA content in Jurkat cells.

Authors:  Rafał Kozieł; Krzysztof Zabłocki; Jerzy Duszyński
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

7.  Fluoroquinolone-induced serious, persistent, multisymptom adverse effects.

Authors:  Beatrice Alexandra Golomb; Hayley Jean Koslik; Alan J Redd
Journal:  BMJ Case Rep       Date:  2015-10-05

Review 8.  Restoration of mitochondria function as a target for cancer therapy.

Authors:  Tariq A Bhat; Sandeep Kumar; Ajay K Chaudhary; Neelu Yadav; Dhyan Chandra
Journal:  Drug Discov Today       Date:  2015-03-09       Impact factor: 7.851

Review 9.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

10.  Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma.

Authors:  Satu J Siiskonen; Els R Koomen; Loes E Visser; Ron M C Herings; Henk-Jan Guchelaar; Bruno H Ch Stricker; Tamar E C Nijsten
Journal:  Eur J Clin Pharmacol       Date:  2013-03-08       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.